Top Abstract Purchase Related
Home
>
Node
>
Subnode

On the Polymorphism of barbiturates in powders and tablets. Part 4: the dissolution of barbital B and barbital a (modifications i and IIi and their release from tablets

Hollenbach, K.; Pintye-Hódi, K.; Kedvessy, G.

Die Pharmazie 35(1): 32-35

1980

ISSN/ISBN: 0031-7144
PMID: 7384174
Document Number: 168053
Two commercial brands of barbital (A: German Democratic Republic, modification III; B: Hungarian Peopl's Republic, modification I) were used to study the solubility and dissolution of the modifications. Crystals of these two substances were brought into the shape of tablets, the physical parameters and textural properties of which were determined. The effect of polymorphism on the release of these substances is discussed in the light of the results obtained from this investigation. The discussion will be continued and summarized in a subsequent paper, including further modifications.

Document emailed within 1 workday
Secure & encrypted payments

Hollenbach, K.; Mezösi, J.; Pintye-Hódi, K.; Kedvessy, G. 1979: On the polymorphism of barbiturates in powders and tablets. Part 2: on the infrared spectroscopy and the X-ray diffractometry of barbital Die Pharmazie 34(4): 240-242
Hollenbach, K.; Pintye-Hódi, K.; Kedvessy, G. 1979: On the polymorphism of barbiturates in powders and tablets. Part 1: Crystal optical studies on, and melting behaviour of barbital Die Pharmazie 34(3): 164-167
Tomassini, L.; Michailova, D.; Naplatanova, D.; Slavtschev, P. 1979: The effects of various factors on the in vitro velocity of drug release from repository tablets. Part 4: Isoniazid (Rimicid) respository tablets Die Pharmazie 34(12): 812-814
Ammar, H.O.; Khalil, R.M. 1996: Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. part 6: rifampicin Die Pharmazie 51(3): 165-168
Traue, J.; Kala, H.; Köhler, M.; Wenzel, U.; Wiegeleben, A.; Pintye-Hódi, K.; Szabó-Révész, P.; Selmeczi, B. 1987: The polymorphism of drugs in powders and tablets. 5. Preparation and characterization of polymorphic forms of tolbutamide Die Pharmazie 42(3): 181-183
Kaiko, R.F.; Fitzmartin, R.D.; Thomas, G.B.; Goldenheim, P.D. 1992: The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets PharmacoTherapy 12(2): 107-113
Chodkowska-Granicka, B.; Pawlak, Z.; Pawlak, E.; Surowiecki, J. 1972: Tablets of 7-(3'-(methylhydroxylethylamino)-2'-hydroxypropyl)-theophylline nicotinate with prolonged action. II. Retardation of the drug release by polymer coating of tablets Acta Poloniae Pharmaceutica 29(6): 618-622
Witchitz, S.; Moisson, P.; Kolsky, H. 1984: A comparative trial of ordinary metoprolol tablets and metoprolol sustained-release tablets in hypertensive patients at rest and on exercise Pharmatherapeutica 3(8): 566-572
Tencova, A.; Kiszeleva, G.; Selmeczi, B.; Kedvessy, G.; Nagy, G. 1984: Technological processes and the influence of adjuvants on the dissolution rate and absorption of some ingredients from tablets. V. Release and absorption capacity of sulfadimidine Acta Pharmaceutica Hungarica 54(6): 245-248
Stozek, T.; Krówczyński, L.; Bohdanowicz, T. 1983: Comparative studies on drug release from tablets in vitro and its biological availability. II. Biological availability of sodium salicylate from tablets of various formulations Acta Poloniae Pharmaceutica 40(1): 77-87
Egli, K.L. 1979: Screening test for amygdalin in tablets, solutions, powders, and seeds Journal - Association of Official Analytical Chemists 62(2): 308-309
Nakashima, M.J.; Angold, S.; Beavin, B.B.; Bradicich, R.B.; Decker, S.J.; Dzidowski, G.R.; Levesque, E.; Locatelli, R.G.; Mably, M.; Paredes, A. 1989: Extraction of light filth from spirulina powders and tablets: collaborative study Journal - Association of Official Analytical Chemists 72(3): 451-453
Ayres, J.W. 1980: Lot-to-lot variation in dissolution of tolbutamide tablets American Journal of Hospital Pharmacy 37(10): 1329-1332
Dávid, A.ám.Z.án.; Lengyel, M.én.; Marton, S.; Klebovich, I.; Antal, I.án. 2005: Example for a new alternative application of NIR spectroscopy in the parallel determination of active ingredients and an excipient in powders and tablets Acta Pharmaceutica Hungarica 75(3): 141-145
Eyjolfsson, R. 2003: Ranitidine tablets: an improved dissolution method Die Pharmazie 58(3): 220
Deák, D.; Pintye-Hódi, K.; Szabó-Révész, P.; Kása, P.; Erós, I.; Muskó, Z. 2000: Mathematical evaluation of the dissolution of metronidazole from tablets Die Pharmazie 55(5): 394-395
Selmeczi, B.; Kedvessy, G.; Nagy, G.; Pintyéné Hódi, K.; Tencova, A.; Kiszeleva, G. 1981: Influence of the technological procedure and additives on the dissolution rate and absorption of active ingredients. I. Physical properties of acetylsalicylic acid tablets and of the dissolution rate of the active ingredient Acta Pharmaceutica Hungarica 51(5): 222-227
Borg, K.O.; Jeppsson, J.; Sjögren, J. 1974: Influence of the dissolution rate of lithium tablets on side-effect Acta Pharmaceutica Suecica 11(2): 133-140
Boymond, C.; Gissinger, D.; Stamm, A. 1982: Effect of various disintegrating agents on the speed of dissolution of phenacetin tablets Pharmaceutica Acta Helvetiae 57(5-6): 131-135
Ayub, S.; Ali, S.A. 1979: Effect of certain tablet formulation factors on dissolution of aspirin tablets Jpma. Journal of the Pakistan Medical Association 29(5): 91-92